Company profile

NGM Biopharmaceuticals

NGM Biopharmaceuticals raised $359 million across several funding rounds, including a $50M Series C (2013), a $57.5M Series D tranche (Feb 2015), and a major $106M Series D round (Mar 2015) led by Merck and top biotech investors. Founded in 2007, the company develops biologics targeting cardio-metabolic and liver diseases such as NASH and bile-acid disorders. Funding supported clinical trials, R&D, manufacturing scale-up and partnerships. These investments helped accelerate NGM’s pipeline toward advanced development stages and grow its capabilities in metabolic and liver therapeutics.

Back to profiles

Quick facts

Total funding: $359 million
Founded: 2007

Notable investors

Merck

Reach buyers like NGM Biopharmaceuticals on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like NGM Biopharmaceuticals
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like NGM Biopharmaceuticals.

The 14-day trial ships every feature, no card required.

Start free →